logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Panel Rejects Hemispherx's Ampligen For Chronic Fatigue Syndrome; Stock Down

Hemispherx Biopharma Inc. (HEB) announced the outcome of the meeting of the Arthritis Advisory Committee of the U.S. Food and Drug Administration on the New Drug Application or "NDA" for Ampligen for Chronic Fatigue Syndrome or "CFS".

The vote was 8 to 5 against recommending the approval of Ampligen. However, the Advisory Committee backed safety profile of Ampligen.

Hemispherx said it is committed to the Ampligen clinical development program and to bringing Ampligen to market to ease the suffering of those seriously afflicted with CFS. The company said it will also continue to work closely with the FDA to support the review of this investigational compound. Hemispherx will seek to do everything necessary to confirm in a scientifically rigorous manner that Ampligen is a safe and effective treatment for CFS.

The Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review of the NDA is February 2, 2013.

HEB is currently trading at $0.28, down $0.08 or 21.39 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Weinstein Co. said it has entered into a preliminary agreement for immediate capital infusion from Colony Capital, the global private equity arm of Colony NorthStar, Inc. In addition, Weinstein Co. has entered into a negotiating period with Colony Capital for a potential sale of all or a significant portion of its assets. Further details of the deal were not disclosed. In the first such incident in Canada, a commercial airplane was struck by a drone last week, the government said Sunday. However, the aircraft was able to land safely. A plane operated by charter airline Skyjet was struck on one of its wings by a drone when it was approaching Quebec City's Jean Lesage International Airport last Thursday. Ford Motor Co. said Friday that it will offer free repairs to North American owners of more than 1.4 million 2011-17 Explorer sports utility vehicles to reduce the potential for exhaust or carbon monoxide entering their vehicles. The recall involves about 1.3 million vehicles in the U.S., 84,000 in Canada and 24,000 in Mexico.
comments powered by Disqus
Follow RTT